3.Identification of a novel germline BRCA2 variant in a male with breast cancer.
Chinese Journal of Medical Genetics 2022;39(3):330-333
OBJECTIVE:
To explore the genetic basis for a male with breast cancer and a sister who had deceased of the disease.
METHODS:
Medical and family history of the proband was collected. Next-generation sequencing was carried out to detect potential variant associated with breast cancer, and Sanger sequencing was used to verify the result.
RESULTS:
The proband was found to harbor a novel heterozygous c.6018dupT variant of the BRCA2 gene which may cause premature termination of mRNA translation, resulting in a truncated protein. Combined with the family history, the variant was deduced to be a germline mutation. Based on the American College of Medical Genetics and Genomics standards and guidelines, c.6018dupT variant of BRCA2 gene was predicted to be pathogenic (PVS1+PM1/2+PP4).
CONCLUSION
The germline variant of the BRCA2 gene probably underlay the breast cancer in this pedigree.
BRCA2 Protein/genetics*
;
Breast Neoplasms, Male/genetics*
;
Genes, BRCA2
;
Genomics
;
Germ Cells
;
Germ-Line Mutation
;
Humans
;
Male
4.Clinical significance of variants of unknown significances in BRCA genes
Journal of Gynecologic Oncology 2019;30(4):e80-
No abstract available.
Genes, Tumor Suppressor
;
BRCA2 Protein
;
BRCA1 Protein
;
Ovarian Neoplasms
;
Breast Neoplasms
5.Novel Germline Mutations of BRCA1 and BRCA2 in Korean Familial Breast Cancer Patients
Hee Nam KIM ; Min Ho SHIN ; Ran LEE ; Min Ho PARK ; Sun Seog KWEON
Chonnam Medical Journal 2019;55(2):99-103
Breast cancer is the second most common cancer in Korean women. Germline mutations in the BRCA1 and BRCA2 genes cause hereditary breast cancer and are detected in 15–20% of hereditary breast cancer. We investigated the BRCA1 and BRCA2 mutations in 114 familial breast cancer patients using next-generation sequencing. We confirmed 20 different mutations of BRCA1 and BRCA2 in 25 subjects (21.9%). Two such mutations in eight patients were novel (not reported in any variant database or previous study). Six mutations have been reported as disease-causing mutations in public databases. Seven mutations were found only in a single nucleotide polymorphism database and one mutation has been reported in Korea. The BRCA1/2 mutation frequency was similar to that of other studies on familial breast cancer patients in the Korean population. Further studies should examine more cases and mutations of whole exons.
BRCA1 Protein
;
BRCA2 Protein
;
Breast Neoplasms
;
Breast
;
Exons
;
Female
;
Genes, BRCA2
;
Germ-Line Mutation
;
Humans
;
Korea
;
Mutation Rate
;
Polymorphism, Single Nucleotide
8.Clinically Significant Unclassified Variants in BRCA1 and BRCA2 genes among Korean Breast Cancer Patients.
Kyong Ah YOON ; Boyoung PARK ; Byung Il LEE ; Moon Jung YANG ; Sun Young KONG ; Eun Sook LEE
Cancer Research and Treatment 2017;49(3):627-634
PURPOSE: Unclassified variants (UVs) of BRCA1 and BRCA2 genes are not defined as pathogenic for breast cancer, and their clinical significance currently remains undefined. Therefore, this study was conducted to identify potentially pathogenic UVs by comparing their prevalence between breast cancer patients and controls. MATERIALS AND METHODS: A total of 328 breast cancer patients underwent BRCA1/2 genetic screening at the National Cancer Center of Korea. Genetic variants of BRCA genes that were categorized as unclassified according to the Breast Cancer Information Core database were selected based on allelic frequency, after which candidate variants were genotyped in 421 healthy controls. We also examined family members of the study participants. Finally, the effects of amino acid substitutions on protein structure and function were predicted in silico. RESULTS: Genetic tests revealed 33 UVs in BRCA1 and 47 in BRCA2. Among 15 candidates genotyped in healthy controls, c.5339T>C in BRCA1 and c.6029T>G, c.7522G>A in BRCA2 were not detected. Moreover, the c.5339T>C variant in the BRCA1 gene was detected in four patients with a family history of breast cancer. This nonsynonymous variant (Leu1780Pro) in the BRCA1 C-terminal domain was predicted to have an effect on BRCA1 protein structure/function. CONCLUSION: This study showed that comparison of genotype frequency between cases and controls could help identify UVs of BRCA genes that are potentially pathogenic. Moreover, ourfindings suggest that c.5339T>C in BRCA1 might be a pathogenic variant for patients and their families.
Amino Acid Substitution
;
BRCA1 Protein
;
Breast Neoplasms*
;
Breast*
;
Computer Simulation
;
Genes, BRCA1
;
Genes, BRCA2*
;
Genetic Testing
;
Genotype
;
Humans
;
Korea
;
Prevalence
9.Analysis of BRCA2 gene mutations among familial and/or early-onset breast cancer patients in eastern Shandong of China.
Zhong-liang MA ; Ming-zhi CAO ; Wen-feng LI
Chinese Journal of Medical Genetics 2008;25(2):195-198
OBJECTIVETo investigate the prevalence of BRCA2 gene mutations among familial and/or early-onset breast cancer patients in eastern Shandong of China.
METHODSFifty-two familial and/or early-onset breast cancer patients from unrelated family were analyzed. Genomic DNA was collected from the peripheral blood mononuclear cells, the coding sequences and exon-intron boundaries of BRCA2 gene were screened using denaturing high performance liquid chromatography (DHPLC), and the abnormal fragments were confirmed with direct DNA sequencing.
RESULTSThree mutations (5.8%) in BRCA2 gene were identified. They were 2001del TTAT, 4099C to T and 5873C to A. To our knowledge, all of them were firstly found in Chinese population. Furthermore, all the three mutations (12%) were identified in familial breast cancer patients, and none was in the early-onset patients.
CONCLUSIONBRCA2 may play an important role in the familial breast cancer in eastern Shandong Chinese population, but not in the early-onset breast cancer. It is necessary to give genetic test to familial breast cancer patients in this population.
Adult ; BRCA2 Protein ; genetics ; Breast Neoplasms ; genetics ; China ; Chromatography, High Pressure Liquid ; Female ; Humans ; Mutation ; Polymerase Chain Reaction
10.The Novel Pathogenic Mutation c.849dupT in BRCA2 Contributes to the Nonsense-Mediated mRNA Decay of BRCA2 in Familial Breast Cancer.
Sanrong LI ; Jing MA ; Caiying HU ; Xing ZHANG ; Deyong XIAO ; Lili HAO ; Wenjun XIA ; Jichun YANG ; Ling HU ; Xiaowei LIU ; Minghui DONG ; Duan MA ; Rensheng LIU
Journal of Breast Cancer 2018;21(3):330-333
In this study, we used next-generation sequencing methods to screen 300 individuals for BRCA1 and BRCA2. A novel mutation (c.849dupT) in BRCA2 was identified in a female patient and her unaffected brothers. This mutation leads to the truncation of BRCA2 functional domains. Moreover, BRCA2 mRNA expression levels in mutation carriers are significantly reduced compared to noncarriers. Immunofluorescence and western blot assays showed that this mutation resulted in reduced BRCA2 protein expression. Thus, we identified a novel mutation that damaged the function and expression of BRCA2 in a family with breast cancer history. The pedigree analysis suggested that this mutation is strongly associated with familial breast cancer. Genetic counsellors suggest that mutation carriers in this family undergo routine screening for breast cancer, as well as other malignancies, such as prostate and ovarian cancer. The effects of this BRCA2 mutation on drug resistance should be taken into consideration during treatment.
Blotting, Western
;
BRCA2 Protein
;
Breast Neoplasms*
;
Breast*
;
Drug Resistance
;
Female
;
Fluorescent Antibody Technique
;
Genes, BRCA2
;
High-Throughput Nucleotide Sequencing
;
Humans
;
Mass Screening
;
Nonsense Mediated mRNA Decay*
;
Ovarian Neoplasms
;
Pedigree
;
Prostate
;
RNA, Messenger
;
Siblings